Skip Nav Destination
Issues
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
Kristina Fanucci; Mary Jo Pilat; Derek Shyr; Yu Shyr; Scott Boerner; Jing Li; Diane Durecki; Jan Drappatz; Vinay Puduvalli; Frank Scott Lieberman; Javier Gonzalez; Pierre Giglio; S. Percy Ivy; Ranjit S. Bindra; Antonio Omuro; Patricia LoRusso
Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction
David C. Florian; Natalie E. Bennett; Mateusz Odziomek; Jessalyn J. Baljon; Mohamed Wehbe; Alyssa R. Merkel; Melissa A. Fischer; Michael R. Savona; Julie A. Rhoades; Scott A. Guelcher; John T. Wilson
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Vigdis Nygaard; Anne Hansen Ree; Vegar Johansen Dagenborg; Anne-Lise Børresen-Dale; Bjørn Edwin; Åsmund Avdem Fretland; Krzysztof Grzyb; Mads H. Haugen; Gunhild M. Mælandsmo; Kjersti Flatmark
Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
Qi Liu; Chenan Zhang; Yue Huang; Ruihao Huang; Shiew-Mei Huang; Erin Larkins; Liza Stapleford; Donna R. Rivera; Paul G. Kluetz; Shenggang Wang; Hao Zhu; James Weese; Elizabeth Cromartie; Mahder Teka; Sheetal Walters; Frank Wolf; Thomas D. Brown
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Derek Wong; Ping Luo; Nadia Znassi; Diana P. Arteaga; Diana Gray; Arnavaz Danesh; Ming Han; Eric Y. Zhao; Stephanie Pedersen; Stephenie Prokopec; Yogi Sundaravadanam; Dax Torti; Kayla Marsh; Sareh Keshavarzi; Wei Xu; Hatem Krema; Anthony M. Joshua; Marcus O. Butler; Trevor J. Pugh
Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming
Marni B. McClure; Yasunori Kogure; Naser Ansari-Pour; Yuki Saito; Hann-Hsiang Chao; Jonathan Shepherd; Mariko Tabata; Olufunmilayo I. Olopade; David C. Wedge; Katherine A. Hoadley; Charles M. Perou; Keisuke Kataoka
Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
Mara P. Steinkamp; Irina Lagutina; Kathryn J. Brayer; Fred Schultz; Danielle Burke; Vernon S. Pankratz; Sarah F. Adams; Laurie G. Hudson; Scott A. Ness; Angela Wandinger-Ness
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
Christianne Groeneveldt; Jurriaan Q. van Ginkel; Priscilla Kinderman; Marjolein Sluijter; Lisa Griffioen; Camilla Labrie; Diana J.M. van den Wollenberg; Rob C. Hoeben; Sjoerd H. van der Burg; Peter ten Dijke; Lukas J.A.C. Hawinkels; Thorbald van Hall; Nadine van Montfoort
Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer
Channing J. Paller; Lin Wang; Wei Fu; Rajendra Kumar; Jennifer N. Durham; Nilofer S. Azad; Daniel A. Laheru; Ilene Browner; Sushant K. Kachhap; Kavya Boyapati; Thomas Odeny; Deborah K. Armstrong; Christian F. Meyer; Stephanie Gaillard; Julie R. Brahmer; Ivelisse Page; Hao Wang; Luis A. Diaz, Jr.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds